We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Molecular Breast Imaging Strategy Reveals More Tumors

By MedImaging International staff writers
Posted on 18 Jun 2014
Print article
Patients with advanced breast cancer that may have metastasized to their lymph nodes could be helped with a stronger dose of a molecular imaging agent called Tc-99m filtered sulfur colloid when undergoing lymphoscintigraphy, a functional imaging approach that searches for new tumors as they begin to metastasize. Best results also indicate that imaging could be improved by injecting the agent the day before surgical resection, according to new research.

The study’s findings were presented at the Society of Nuclear Medicine and Molecular Imaging’s 2014 annual meeting, held June 7-11, 2014, in St. Louis (MO, USA). “The innovative aspect of this study was our recent introduction of day-before-surgery injections for breast cancer patients,” said Donald Neumann, MD, research scientist and practicing physician from the department of nuclear medicine at the Cleveland Clinic (Cleveland, OH, USA). “Prior to this, we routinely injected patients on the day of surgery. There were several motivating factors for us to do this. Typically, surgeries begin very early in the morning, and it is very difficult to arrange all the necessary equipment, personnel, and radiotracers early enough in the morning for patients to be injected, scanned, have their images interpreted and travel [or be transported] to surgical check-in.”

The researchers also enhanced the activity of the agent as imaged by lymphoscintigraphy by increasing the standard patient dose to 3.0 millicuries of Tc-99m filtered sulfur colloid up from 0.4 millicuries.

The change in injection timing from the morning of surgery to the day prior to surgery was based on study data. Of a group of 51 patients who were imaged the day prior, 39 had cancer that had spread to their lymph nodes and 12 patients’ scans demonstrated multiple lymph node malignancies. A separate group of 49 patients were injected with the agent the morning of their surgery. Of these, 24 patients had cancer that had metastasized to their lymph nodes. Imaging performed the morning before resulted in being more sensitive for the identification of advanced breast cancer than the day of, 76% sensitive versus 49%, respectively.

Related Links:

Cleveland Clinic


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Ultrasound Software
UltraExtend NX
Under Table Shield
3 Section Double Pivot Under Table Shield
New
X-Ray Detector
FDR-D-EVO III

Print article

Channels

Radiography

view channel
:	Image: The AI model could be a valuable adjunct to human radiologists in breast cancer diagnoses and risk prediction (Photo courtesy of 123RF)

AI Model Predicts 5-Year Breast Cancer Risk from Mammograms

Approximately 13% of U.S. women, or one in every eight, are predicted to develop invasive breast cancer over their lifetime, with 1 in 39 women (3%) succumbing to the illness, according to the American... Read more

General/Advanced Imaging

view channel
Image: The Cinematic Reality app enables interaction with realistic renderings of human anatomy (Photo courtesy of Siemens)

AR Application Turns Medical Scans Into Holograms for Assistance in Surgical Planning

Siemens Healthineers (Erlangen, Germany) has launched an app designed for Apple Vision Pro that allows users including surgeons, medical students, or patients to view immersive, interactive holograms of... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: Samsung Medison CEO Mr. Yongkwan Kim and Bracco Imaging CEO Dr. Fulvio Renoldi Bracco endorsed a MoU agreement (Photo courtesy of Bracco Group)

Samsung and Bracco Enter Into New Diagnostic Ultrasound Technology Agreement

Samsung Medison (Seoul, South Korea) and Bracco Imaging (Milan, Italy) have entered into a Memorandum of Understanding (MoU) agreement to pioneer a new area for diagnostic ultrasound devices and contrast agents.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.